Safety of biologics in psoriasis
Author:
Affiliation:
1. Department of Dermatology; Teikyo University School of Medicine; Tokyo Japan
Publisher
Wiley
Subject
Dermatology,General Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/1346-8138.14096/fullpdf
Reference116 articles.
1. Psoriasis and comorbid diseases: epidemiology;Takeshita;J Am Acad Dermatol,2017
2. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial;Gottlieb;J Am Acad Dermatol,2004
3. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT);Antoni;Arthritis Rheum,2005
4. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial;Reich;Lancet,2005
5. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis;Menter;J Am Acad Dermatol,2007
Cited by 105 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Deucravacitinib: moderate-to-severe plaque psoriasis preventable?;Journal of Basic and Clinical Physiology and Pharmacology;2024-07-09
2. Targeted therapy for immune mediated skin diseases. What should a dermatologist know?;Anais Brasileiros de Dermatologia;2024-07
3. Posidonia oceanica (L.) Delile Is a Promising Marine Source Able to Alleviate Imiquimod-Induced Psoriatic Skin Inflammation;Marine Drugs;2024-06-28
4. Disparities and barriers to the access of biologics in moderate‐to‐severe adult psoriasis;International Journal of Dermatology;2024-06-06
5. Interleukin‐23 inhibitors decrease Fibrosis‐4 index in psoriasis patients with elevated Fibrosis‐4 index but not inteleukin‐17 inhibitors;The Journal of Dermatology;2024-05-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3